Cerebrolysin for early rehabilitation after acute ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study at UMC Ljubljana compares patients receiving Cerebrolysin plus standard acute care and early neurorehabilitation to a control group receiving standard care alone. Eligible participants have imaging-confirmed acute ischemic stroke with moderate deficits (NIHSS 6–12) and must be able to perform the Action Research Arm Test (ARAT). Cerebrolysin is a low-molecular-weight peptide preparation derived from porcine brain given as an adjunct during the early rehabilitation period, and the trial tracks motor recovery and safety outcomes. Clinical measures and adverse events are recorded and compared between groups to determine whether Cerebrolysin adds benefit to routine rehabilitation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Being able to perform ARAT test Signed informed consent

Both sexes, age not specified

Acute ischemic stroke confirmed by imaging

NIHSS score 6-12

No prior stroke or disability (mRS 0 before stroke)

\-

Exclusion Criteria:

Not being able to perform ARAT test

* Previous stroke or disability (mRS \> 0)
* The patient unable to understand instructions

Where it's running

• UMC Ljubljana - Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT)
  Ljubljana, Slovenia Recruiting

Study contacts

• Principal investigator: Matija Zupan, MD, PhD — University Medical Centre Ljubljana
• Study coordinator: Matija Zupan, MD, PhD
• Email: matija.zupan@kclj.si
• Phone: 0038615229581

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-powered decision support to boost thrombolysis for ischemic stroke

  This trial tests whether an AI-assisted decision tool helps doctors give intravenous thrombolysis to eligible ischemic stroke patients within 24 hours at a primary hospital in China, compared with standard care.

  Recruiting Capital Medical University · Changsha, Hunan · NCT07785492

• Tegoprazan to prevent GI complications in ischemic stroke patients on antiplatelet therapy

  This trial tests whether tegoprazan can lower gastrointestinal complications in adults with ischemic stroke or TIA who are starting antiplatelet therapy.

  Recruiting at 24 sites Phase 3 Hanyang University · Busan, Busan and 23 other locations · NCT07687706

• Intra-arterial Thrombolysis for Acute Ischemic Stroke with Medium Vessel Occlusion

  This trial tests whether delivering a clot-busting medicine directly into the brain’s medium vessels helps improve outcomes for adults with acute ischemic stroke caused by MeVO, on top of standard care.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07668323

• Single Bolus Non-immunogenic Staphylokinase in Acute Ischemic Stroke (4.5–24 hours)

  This trial tests a single 10 mg bolus of non-immunogenic staphylokinase versus placebo in adults with acute ischemic stroke 4.5–24 hours after onset to see if it helps restore blood flow and improve outcomes.

  Recruiting at 10 sites Phase 3 Supergene, LLC · Ryazan, Ryazan Oblast and 16 other locations · NCT07324837

• PEARL: Rehabilitation and recovery after atrial fibrillation-related ischemic stroke

  This project will see if adults with atrial fibrillation-related ischemic stroke have different rehabilitation needs and whether higher-intensity inpatient therapy (3–5 sessions/day) leads to better functional recovery at six months than moderate-intensity care (1 session/day).

  Recruiting Parc de Salut Mar · Barcelona · NCT07253974

• Imaging to detect impaired microcirculatory reperfusion after clot removal

  This project tests whether CT perfusion scans done after clot removal can spot poor tiny-vessel blood flow in adults with large-vessel ischemic stroke.

  Recruiting University of Cincinnati · Cincinnati, Ohio · NCT07099599

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.